The high need for trials assessing functional outcome after stroke rather than stroke prevention with GLP-1 agonists and DPP-4 inhibitors

被引：0
|
作者：
Vladimer Darsalia
Martin Larsson
Thomas Klein
Cesare Patrone
机构：
[1] Karolinska Institutet,Department of Clinical Science and Education, Södersjukhuset, Internal Medicine
[2] Boehringer Ingelheim Pharma GmbH & Co. KG,undefined
来源：
Cardiovascular Diabetology | / 17卷
关键词：
Glucagon-like peptide 1 receptor; Dipeptidyl peptidase-4 inhibitors; Stroke; Diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] DPP-4 inhibitors and GLP-1 agonists in type 2 diabetes - early assessment of cardiovascular safety in a nationwide setting
    Mogensen, U. M.
    Andersson, C.
    Fosbol, E. L.
    Schramm, T. K.
    Vaag, A.
    Scheller, N. M.
    Pedersen, C. T.
    Gislason, G.
    Kober, L.
    EUROPEAN HEART JOURNAL, 2013, 34 : 1111 - 1111
  • [32] Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to Glucagon-Like Peptide-1 (GLP-1) agonists: No
    Madsbad, Sten
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2012, 23 (02) : 132 - 136
  • [33] Incretin-based medications (GLP-1 receptor agonists, DPP-4 inhibitors) as a means to avoid hypoglycaemic episodes
    Farngren, Johan
    Ahren, Bo
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2019, 99 : 25 - 31
  • [34] Glucagon-like receptor 1 agonists and DPP-4 inhibitors: potential therapies for the treatment of stroke
    Darsalia, Vladimer
    Larsson, Martin
    Nathanson, David
    Klein, Thomas
    Nystrom, Thomas
    Patrone, Cesare
    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2015, 35 (05): : 718 - 723
  • [35] Association of SGLT2 Inhibitors and DPP-4 Inhibitors vs. GLP-1 Agonists with Incident CKD in US Veterans
    Kalantar-Zadeh, Kamyar
    Rhee, Connie
    Narasaki, Yoko
    You, Amy S.
    Dashputre, Ankur A.
    Sumida, Keiichi
    Thomas, Fridtjof
    Streja, Elani
    Potukuchi, Praveen Kumar
    Kovesdy, Csaba P.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 697 - 698
  • [36] GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?
    Brunton, S.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2014, 68 (05) : 557 - 567
  • [37] Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: Yes
    Scheen, Andre J.
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2012, 23 (02) : 126 - 131
  • [38] Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors
    Donna Shu-Han Lin
    Jen-Kuang Lee
    Wen-Jone Chen
    Diabetologia, 2021, 64 : 1949 - 1962
  • [39] Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors
    Lin, Donna Shu-Han
    Lee, Jen-Kuang
    Chen, Wen-Jone
    DIABETOLOGIA, 2021, 64 (09) : 1949 - 1962
  • [40] Comparative Cardiovascular Efficacy of SGLT2 Inhibitors, DPP-4 Inhibitors, and GLP-1 Agonists-A Network Meta-analysis
    Roddick, Alistair J.
    Zheng, Sean
    DIABETES, 2018, 67
12345